Dave: good post. Yes, the AMBS strategy makes perfect sense. When I called NanoSomix they said 'there is room for many Biomarkers' in Alzheimer's diagnosis. Look like AMBS will have a portfolio of Alzheimer's diagnostic options limiting the value of going to NanoSomix. Wouldn't be surprised if NanoSomix gets purchased if you know what I mean.